p38 mitogen-activated protein kinase-dependent tumor necrosis factor-α-converting enzyme is important for liver injury in hepatotoxic interaction between lipopolysaccharide and ranitidine

被引:14
作者
Deng, Xiaomin [2 ]
Lu, Jingtao [2 ]
Lehman-McKeeman, Lois D. [3 ]
Malle, Ernst [4 ]
Crandall, David L. [5 ]
Ganey, Patricia E. [1 ]
Roth, Robert A. [1 ]
机构
[1] Michigan State Univ, Dept Pharmacol & Toxicol, E Lansing, MI 48824 USA
[2] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA
[3] Bristol Myers Squibb Co, Discovery Toxicol, Princeton, NJ USA
[4] Med Univ Graz, Ctr Mol Med, Inst Mol Biol & Biochem, Graz, Austria
[5] Wyeth Ayerst Res, Philadelphia, PA USA
基金
奥地利科学基金会;
关键词
D O I
10.1124/jpet.108.137497
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ranitidine (RAN) is one of the drugs associated with idiosyncratic adverse drug reactions (IADRs) in human patients. In rats, cotreatment with nontoxic doses of lipopolysaccharide (LPS) and RAN causes liver injury. This is a potential animal model for RAN-induced IADRs in humans. Previous studies showed that RAN augmented serum tumor necrosis factor (TNF)-alpha production and hepatic neutrophil activation after LPS treatment and that both TNF-alpha and neutrophils are crucial for the liver pathogenesis. We tested the hypothesis that p38 mitogen-activated protein kinase activation is necessary for TNF-alpha production, neutrophil activation, and subsequent liver injury. LPS/RAN cotreatment caused more p38 activation compared with LPS alone. The p38 inhibitor SB 239063 [trans-1-(4-hydroxycyclohexyl)-4-(4-fluorophenyl)-5-(2-methoxypyridimidin-4-yl) imidazole] reduced liver injury in rats cotreated with LPS/RAN. This inhibitor also reduced neutrophil activation and attenuated hemostatic system activation. SB 239063 decreased serum TNF-alpha concentration after LPS/RAN treatment to the same level as LPS treatment. However, the inhibitor did not reduce TNF-alpha mRNA in liver, suggesting a post-transcriptional mode of action. This might occur through TNF-alpha-converting enzyme (TACE), which cleaves pro-TNF-alpha into its active form. Indeed, a TACE inhibitor administered just before RAN treatment reduced serum TNF-alpha protein. The TACE inhibitor also reduced liver injury and serum plasminogen activator inhibitor (PAI)-1. Furthermore, a PAI-1 inhibitor reduced neutrophil activation and liver injury after LPS/RAN treatment. In summary, RAN enhanced TNF-alpha production after LPS treatment through augmented p38 activation, and this seems to occur through TACE. The prolonged TNF-alpha production enhanced PAI-1 production after RAN cotreatment, and this is important for the hepatotoxicity.
引用
收藏
页码:144 / 152
页数:9
相关论文
共 39 条
[1]  
AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345
[2]  
Barone FC, 2001, J PHARMACOL EXP THER, V296, P312
[3]   Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3) [J].
Bourdet, DL ;
Pritchard, JB ;
Thakker, DR .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) :1288-1297
[4]  
CHERQUI B, 1989, GASTROEN CLIN BIOL, V13, P952
[5]   Endothelial cell injury and fibrin deposition in rat liver after monocrotaline exposure [J].
Copple, BL ;
Banes, A ;
Ganey, PE ;
Roth, RA .
TOXICOLOGICAL SCIENCES, 2002, 65 (02) :309-318
[6]   Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy [J].
Crandall, DL ;
Elokdah, H ;
Di, L ;
Hennan, JK ;
Gorlatova, NV ;
Lawrence, DA .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (08) :1422-1428
[7]   Neutrophil interaction with the hemostatic system contributes to liver injury in rats cotreated with lipopolysaccharide and ranitidine [J].
Deng, Xiaomin ;
Luyendyk, James P. ;
Zou, Wei ;
Lu, Jingtao ;
Malle, Ernst ;
Ganey, Patricia E. ;
Roth, Robert A. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 322 (02) :852-861
[8]   Ectodomain shedding of TGF-α and other transmembrane proteins is induced by receptor tyrosine kinase activation and MAP kinase signaling cascades [J].
Fan, HZ ;
Derynck, R .
EMBO JOURNAL, 1999, 18 (24) :6962-6972
[9]   Nephrotoxicity and hepatotoxicity of histamine H2 receptor antagonists [J].
Fisher, AA ;
Le Couteur, DG .
DRUG SAFETY, 2001, 24 (01) :39-57
[10]   PROCESSING OF TUMOR-NECROSIS-FACTOR-ALPHA PRECURSOR BY METALLOPROTEINASES [J].
GEARING, AJH ;
BECKETT, P ;
CHRISTODOULOU, M ;
CHURCHILL, M ;
CLEMENTS, J ;
DAVIDSON, AH ;
DRUMMOND, AH ;
GALLOWAY, WA ;
GILBERT, R ;
GORDON, JL ;
LEBER, TM ;
MANGAN, M ;
MILLER, K ;
NAYEE, P ;
OWEN, K ;
PATEL, S ;
THOMAS, W ;
WELLS, G ;
WOOD, LM ;
WOOLLEY, K .
NATURE, 1994, 370 (6490) :555-557